There are 2789 resources available
663P - First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
Presenter: Camillo Guglielmo Porta
Session: ePoster Display
704P - Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA
Presenter: Alicia Morgans
Session: ePoster Display
741P - Immune features of high-grade ovarian cancer associated with exceptional disease free survival (DFS): An analysis from VIVROVAIRE, a GINECO/GINEGEPS study
Presenter: Louis Mourani
Session: ePoster Display
621P - Efficacy and safety of relugolix vs leuprolide (LEU) in men with advanced prostate cancer (APC): Clinical subgroup analysis from the phase III HERO study
Presenter: Bertrand Tombal
Session: ePoster Display
747P - Real-world experience of rucaparib in patients with ovarian cancer: A multicentre United Kingdom study
Presenter: Mark Lythgoe
Session: ePoster Display
748P - Real-world-data (RWD) on platinum (Pt)-based chemotherapy (CT) after PARP inhibitors (PARPi) in high-grade serous (or endometrioid) ovarian cancer (HGSEOC)
Presenter: Margarita Romeo Marin
Session: ePoster Display
1655P - Real-world outcome of patients with relapsed or refractory small cell lung cancer treated with checkpoint inhibitors in Tertiary Care Centers across Germany
Presenter: Jan Stratmann
Session: ePoster Display
1656P - Germline mutations in DNA damage repair genes in patients with small cell lung cancer
Presenter: Yu Feng
Session: ePoster Display
1657P - Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study
Presenter: Bing Xia
Session: ePoster Display
1658P - Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)
Presenter: Andrea Plaja
Session: ePoster Display